MENU
+Compare
JUNS
Stock ticker: NASDAQ
AS OF
Jun 16 closing price
Price
$0.94
Change
-$0.19 (-16.81%)
Capitalization
31.12M

JUNS Jupiter Neurosciences Inc Forecast, Technical & Fundamental Analysis

Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida... Show more

JUNS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for JUNS with price predictions
Jun 16, 2025

JUNS in -1.95% downward trend, falling for three consecutive days on May 21, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where JUNS declined for three days, in of 33 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

JUNS broke above its upper Bollinger Band on June 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for JUNS entered a downward trend on May 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Momentum Indicator moved above the 0 level on May 28, 2025. You may want to consider a long position or call options on JUNS as a result. In of 6 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for JUNS just turned positive on May 23, 2025. Looking at past instances where JUNS's MACD turned positive, the stock continued to rise in of 1 cases over the following month. The odds of a continued upward trend are .

JUNS moved above its 50-day moving average on May 28, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +12 3-day Advance, the price is estimated to grow further. Considering data from situations where JUNS advanced for three days, in of 23 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JUNS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.152) is normal, around the industry mean (17.019). P/E Ratio (0.000) is within average values for comparable stocks, (59.606). JUNS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.319). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (257.445).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JUNS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
JUNS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

JUNS is expected to report earnings to rise 40.00% to -7 cents per share on September 03

Jupiter Neurosciences Inc JUNS Stock Earnings Reports
Q2'25
Est.
$-0.07
Q1'25
Missed
by $0.02
Q4'24
Est.
$-0.02
Q3'24
Est.
$-0.02
The last earnings report on May 28 showed earnings per share of -5 cents, missing the estimate of -2 cents. With 324.98K shares outstanding, the current market capitalization sits at 31.12M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSMGX26.900.30
+1.13%
Janus Henderson Triton I
GSMQX18.22N/A
N/A
Goldman Sachs Small/Mid Cap Growth Svc
GASFX28.40N/A
N/A
Hennessy Gas Utility Investor
LHCAX18.21N/A
N/A
Lord Abbett Health Care A
VYMRX15.91N/A
N/A
Voya Mid Cap Research Enhanced Index C